Global Blood Therapeutics (GBT) Data 'Exceeded Our High Expectations' - Cowen
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/3/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
- Analysis-Excommunications show a Pope Leo unafraid of making firm decisions
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Canaccord Starts Infleqtion, Inc (INFQ) at Buy
- Jersey Mike's Subs files for IPO on NYSE under ticker JMKE
- AXT-Tongmei signs 3-year wafer supply deal with Coherent
Global Blood Therapeutics (GBT) Gains on Positive Results from Ongoing Sickle Cell Drug Trial
June 10, 2016 9:07 AM EDTGlobal Blood Therapeutics (NASDAQ: GBT) is gaining 21% pre-open trade after the company... More
Global Blood Therapeutics (GBT) Announces New Results from Ongoing Phase 1/2 GBT440-001 Study in Sickle Cell Disease
June 10, 2016 8:01 AM EDTGlobal Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT), a biopharmaceutical company developing novel therapeutics for the treatment of grievous blood-based disorders with significant unmet needs, today announced new results from its ongoing Phase 1/2 GBT440-001 study in sickle cell disease (SCD) that further support the company's plans to develop GBT440 as a potential disease-modifying therapy for SCD. The data being presented today at the European Hematology Association's (EHA) 21st Congress in Copenhagen include a poster presentation of... More
